Genmab
Research Genmab (GMAB) on Bullrun: valuation model: 20.4% overvalued, market cap USD 22.13B, P/E 29.4. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerGMAB
- ExchangeNASDAQ
- CountryDenmark
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Valuation signal20.4% overvalued
- Market capUSD 22.13B
- P/E29.4
- Financial periodQ2 2026
- RevenueUSD 1.16B
- Net incomeUSD 303.00M
- Free cash flowUSD 48.00M
- Gross margin92.7%
Valuation Snapshot
Bullrun's latest valuation model marks Genmab as 20.4% overvalued; latest market cap is USD 22.13B; P/E is 29.4.
Peer valuation comparison
Latest P/E is 29.36x versus a Healthcare sector median of 24.61x (19.3% above).
Latest P/E is 29.36x versus a Denmark median of 17.65x (66.4% above).
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 3.72B | USD 963.00M | USD 1.13B | 93.6% | 1.54 | USD 1.72B | USD 5.43B | USD 5.85B |
| FY2024 | USD 3.12B | USD 1.13B | USD 1.08B | 95.4% | 1.69 | USD 1.38B | USD 144.00M | USD 5.14B |
| FY2023 | USD 2.39B | USD 631.00M | USD 1.02B | 98.6% | 0.96 | USD 2.20B | USD 114.00M | USD 4.69B |
| FY2022 | USD 2.09B | USD 784.70M | USD 517.42M | 100.0% | 1.2 | USD 1.42B | USD 85.93M | USD 3.93B |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-09 | USD 22.13B | 29.4 | n/a | n/a |
| 2025 | 2025-12-31 | USD 18.97B | 19.9 | n/a | n/a |
| 2024 | 2024-12-31 | USD 13.26B | 11.9 | n/a | n/a |
| 2023 | 2023-12-29 | USD 20.80B | 34.2 | n/a | n/a |
| 2022 | 2022-12-30 | USD 27.95B | 35.0 | n/a | n/a |
| 2021 | 2021-12-31 | USD 26.00B | 54.9 | n/a | n/a |
About Genmab
Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large B-cell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy.
ETFs that hold Genmab
Genmab is one of the ten largest holdings of 4 ETFs that investors in Europe can buy, most traded first:
| ETF | Weight | TER |
|---|---|---|
| iShares Healthcare Innovation UCITS ETF USD (Acc) | 1.73% | 0.40% |
| iShares Ageing Population UCITS ETF USD (Acc) | 0.70% | 0.40% |
| First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation | 3.75% | 0.60% |
| iShares MSCI Europe Mid-Cap Equal Weight UCITS ETF | 0.64% | 0.25% |
Related stock research
Other Healthcare stocks
Frequently asked questions
Is Genmab overvalued or undervalued?
Bullrun's valuation model currently marks Genmab as 20.4% overvalued.
What is Genmab's market cap?
Genmab's market capitalization is USD 22.13B.
What is Genmab's P/E ratio?
Genmab's price-to-earnings (P/E) ratio is 29.4.
What does Genmab do?
Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large B-cell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy.